Streetwise Reports' Article Archives — June 2021 back to current month (26)
The investment thesis for Mydecine Innovations Group is presented in a ROTH Capital Partners report.
Repurposing extends a drug's reach and value, and Algernon Pharmaceuticals' strategy of finding and demonstrating new uses for existing drugs reduces risk, accelerates time to market and increases capital efficiency.
Kronos Bio's key assets are reviewed in an H.C. Wainwright & Co. report.
Shares of Cerevel Therapeutics hit a new 52-week high after the company released positive topline results for its CVL-231 in a Phase 1b clinical trial in schizophrenia patients.
Intellia Therapeutics soared to a new 52-week high after the firm reported that in a Phase 1 clinical study with partner Regeneron, it had achieved "landmark clinical data" that demonstrated deep reduction in disease-causing protein after a single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis.
Eli Lilly and Co's shares traded 8% higher and reached a new 52-week high after the company reported the FDA granted its investigational antibody therapy donanemab Breakthrough Therapy designation for use in treating Alzheimer's disease.
Aclaris Therapeutics' new clinical trial data and a recent financing are discussed in an H.C. Wainwright & Co. report.
These new results, from a Clearside Biomedical trial, are presented and interpreted in a ROTH Capital Partners report.
How the acquisition has grown and its effects on CloudMD Software & Services are addressed in a Research Capital Corp. report.
3D Systems Corp. shares rose 27% after the company reported it is partnering with CollPlant Biotechnologies to develop bioprinted solutions use to improve breast reconstruction treatments.
Anavex Life Sciences shares traded 13% higher after the company reported that ANAVEX®2-73 (blarcamesine) biomarker correlated highly with the predetermined efficacy endpoints in its Phase 2 clinical trial of adult patients with Rett syndrome.
Entera Bio shares traded 25% higher after the firm received a foundational patent from the EU patent office for its oral parathyroid hormone using its platform oral protein delivery technology to treat osteoporosis and hypoparathyroidism.
These data and next steps for Novan's antiviral SB019 are provided in a ROTH Capital Partners report.
The status of ONCOS-102 in several of Targovax's development programs is discussed in an H.C. Wainwright & Co. report.
Altimmune Inc. shares traded 16% higher after the company reported positive interim data from a Phase 1 study of ALT-801 in overweight and obese trial participants.
Clearside Biomedical shares reached a new 52-week high after the company reported that the first cohort in its dose-escalating Oasis Trial of CLS-AX for treatment of neovascular age-related macular degeneration met all primary endpoints.
Shares of Enochian Biosciences Inc. traded higher after the company reported that the U.S. Food and Drug Administration accepted a pre-investigational new drug request for a potential functional cure or treatment for human immunodeficiency virus.
Sorrento's COVID Test Approved in Mexico (06/09/2021)
This and other recent developments involving Sorrento Therapeutics' pipeline and partners are covered in a Dawson James Securities report.
Tilray Inc. shares traded 11% higher after the company reported the launch of a new medical cannabis brand, Symbios, designed to provide medicinal users with a broader spectrum of formats and cannabinoid potencies at improved price points.
McAlinden Research Partners notes that continued advances in psychedelic therapies show potential to drive an investment boom that could reshape the future of medicine and mental health therapies.
Kindred Biosciences Inc. shares reached a new 52-week high after the company reported its parvovirus monoclonal antibody, KIND-030, demonstrated highly positive results in preventing deaths in dogs infected by parvovirus.
Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors.
Avivagen's OxC-beta™ Livestock products could play a pivotal role in the global mandate to remove all in-feed antibiotics as growth promoters.
The award and other recent developments at Anixa Biosciences are covered in an H.C. Wainwright & Co. report.
Applied DNA Sciences' SARS-CoV-2 mutation panel and its validation are discussed in a ROTH Capital Partners report.
Shares of Constellation Pharmaceuticals Inc. traded 65% higher after the company reported it entered into an agreement to be acquired by MorphoSys AG in an all-cash transaction for $34 per share.
|"Data presented by peers at the CTAD conference are relevant to PMN."|